Department of Surgical Oncology and Gastroenterological Surgery, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo, 060-8543, Japan.
J Hepatobiliary Pancreat Sci. 2013 Jan;20(1):8-23. doi: 10.1007/s00534-012-0564-0.
While referring to the evidence adopted in the Tokyo Guidelines 2007 (TG07) as well as subsequently obtained evidence, further discussion took place on terminology, etiology, and epidemiological data. In particular, new findings have accumulated on the occurrence of symptoms in patients with gallstones, frequency of severe cholecystitis and cholangitis, onset of cholecystitis and cholangitis after endoscopic retrograde cholangiopancreatography and medications, mortality rate, and recurrence rate. The primary etiology of acute cholangitis/cholecystitis is the presence of stones. Next to stones, the most significant etiology of acute cholangitis is benign/malignant stenosis of the biliary tract. On the other hand, there is another type of acute cholecystitis, acute acalculous cholecystitis, in which stones are not involved as causative factors. Risk factors for acute acalculous cholecystitis include surgery, trauma, burn, and parenteral nutrition. After 2000, the mortality rate of acute cholangitis has been about 10 %, while that of acute cholecystitis has generally been less than 1 %. After the publication of TG07, diagnostic criteria and severity assessment criteria were standardized, and the distribution of cases according to severity and comparison of clinical data among target populations have become more subjective. The concept of healthcare-associated infections is important in the current treatment of infection. The treatment of acute cholangitis and cholecystitis substantially differs from that of community-acquired infections. Cholangitis and cholecystitis as healthcare-associated infections are clearly described in the updated Tokyo Guidelines (TG13). Free full-text articles and a mobile application of TG13 are available via http://www.jshbps.jp/en/guideline/tg13.html.
在参考 2007 年《东京指南》(TG07)采用的证据以及随后获得的证据的同时,还就术语、病因学和流行病学数据进行了进一步的讨论。特别是,关于胆结石患者出现症状的新发现、胆囊炎和胆管炎的严重程度、内镜逆行胰胆管造影术和药物治疗后胆囊炎和胆管炎的发病时间、死亡率和复发率等方面,积累了新的研究结果。急性胆囊炎/胆管炎的主要病因是结石。除了结石之外,急性胆管炎最主要的病因是胆管的良性/恶性狭窄。另一方面,还有另一种类型的急性胆囊炎,即无结石的急性胆囊炎,在这种情况下,结石不是致病因素。急性非结石性胆囊炎的危险因素包括手术、外伤、烧伤和肠外营养。自 2000 年以来,急性胆管炎的死亡率约为 10%,而急性胆囊炎的死亡率一般低于 1%。在 TG07 发布后,诊断标准和严重程度评估标准得到了标准化,根据严重程度对病例进行了分类,并对目标人群的临床数据进行了比较,变得更加主观。在当前的感染治疗中,与医疗保健相关的感染的概念非常重要。急性胆管炎和胆囊炎的治疗与社区获得性感染的治疗有很大不同。作为与医疗保健相关的感染的胆管炎和胆囊炎在更新的《东京指南》(TG13)中有明确的描述。可通过 http://www.jshbps.jp/en/guideline/tg13.html 免费获取全文文章和 TG13 的移动应用程序。